Raman Pharma is a UK based MHRA and VMD Licensed Wholesaler supplying to the Human and Veterinary Market. We are a family run company ambitiously changing the face of the Pharmaceutical and Veterinary Market alike in order to serve the needs of our customers and their patients.
Our Philosophy and business are structured around the requirements of our customers and we are committed to giving them our upmost attention and care. We believe in delivering quality and value to our customers wherever they may be.
The Herbal Horse and Pet is a South African manufacturer of a very innovative range of supplements for horses, dogs and cats. Their philosophy of using a large number of different ingredients in small amounts mimics nature in that the healing effect of the ingredients is maximised while undesirable side-effects are minimised. These unique formulations, in conjunction with 21st century scientific research and techniques are what they call “cutting edge nature”.
They are manufactured in a GMP Compliant Factory and has a large following from riders and pet owners across the world. Please follow the link to the website – www.theherbalhorse.co.uk to see all the amazing blogs and the ability to purchase these products online. The Equine and Pet Range were introduced to the UK Market in September 2014 by Raman Pharma to give the UK a taste of the future in equine and companion animal nutritional supplements.
"Fantastic service, Really helpful & always able to source products that we need at very competitive prices. Would thoroughly recommend to any Veterinary Practice"
"Raman Pharma have been invaluable in sourcing drugs that are out of stock elsewhere. Delivery is rapid, costs are good and the customer service provided by Dhruv is excellent. I would definitely recommend this company and its services to others."
The Department of Health and Social Care (DHSC) has provided an update on the Serious Shortage Protocols (SSPs) for Salazopyrin® EN-Tabs 500mg (SSP08). SSP08 for Salazopyrin® EN-Tabs 500mg was previously expected to expire on 22nd January 2021 but the end date has been further extended to 26th February 2021. Please note: expiry dates of an...
NHS England and NHS Improvement (NHSE&I) has today (21st January 2021), announced that funding for the Community Pharmacist Consultation Service (CPCS) IT systems has been extended for an extra six months – until 30th September 2021. Since March 2020, monies from the Pharmacy Integration Fund have been provided to NHSE&I regional teams to fund CPCS...
A second wave of community pharmacies have joined the NHS COVID-19 vaccination programme. The 65 pharmacy-run sites began offering vaccination appointments from 8am today (Thursday 21st January). Playing to the strengths of community pharmacies as socially inclusive healthcare providers, the majority of the sites are in areas where they are best placed to reach groups at...
PSNC has launched a video animation and infographic explaining how GP practices can refer into the NHS Community Pharmacist Consultation Service (CPCS). The digital explainers have been developed to help describe the GP referral pathway into the CPCS. The animation outlines how referrals work and what pharmacies do with those referrals, as well as the...
The General Pharmaceutical Council have published new standards for the initial education and training of pharmacists. The implementation of these standards will transform the education and training of pharmacists, so they are able to play a much greater role in providing clinical care to patients and the public from their first day on the register,...
The Declaration of Competence (DoC) to support provision of the Discharge Medicines Service (DMS) is now available on the Centre for Pharmacy Postgraduate Education (CPPE) website. The DMS will be an Essential service within the NHS Community Pharmacy Contractual Framework from 15th February 2021. This DoC must be completed by all pharmacists and pharmacy technicians...
Community pharmacy contractors can now access guidance about the upcoming PSNC Pharmacy Advice Audit for 2021, including full details of how to take part. As announced last week, pharmacy teams are being encouraged to take part in an audit that will capture information about the reasons why people choose to visit community pharmacies. PSNC is increasingly...
This briefing describes how community pharmacy teams can take part in PSNC’s audit to capture information about the reasons why people choose to visit community pharmacies. PSNC Briefing 001/21: PSNC Pharmacy Advice Audit 2021 – Team Briefing Sheet Related document: Audit Template If you have any queries on this PSNC Briefing or you require more...
Yesterday, Nadhim Zahawi, Minister for COVID Vaccination Deployment made a statement on the provision of indemnity for the vaccination programme, including provision by community pharmacy in England. The Minister’s statement provides clarity on why the indemnity has been provided to community pharmacy and also extends the scheme to 30th June 2021. He stated: “Without adequate...
CLDA number: CLDA (21)A/01 Date issued: 18th January 2021 The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a company-led drug recall for: Instanyl 100mcg nasal spray solution Product Batch number Expiry Date Pack Size First Distributed Instanyl 100mcg Nasal Spray 447055 31/10/2021 1 x 6 single dose containers 14/04/2020 Takeda UK Limited is...
EAMS scientific opinion issued to Incyte Biosciences UK Ltd for pemigatinib in the treatment of adults with locally advanced or metastatic cholangiocarcinoma with fibroblast growth factor receptor 2 fusion or rearrangement that is relapsed or refractory after at least one line of systemic therapy.
The approach the MHRA intends to take for products approved or pending in decentralised procedure (DCP) or mutual recognition procedures (MRP).
The different types of tests and testing kits for COVID-19, and the specifications for manufacturers.
CSL Behring UK Ltd is recalling specific batches of Respreeza 1,000 mg powder and solvent for solution for infusion (EU/1/15/1006/001) due to a manufacturing deviation that occurred during the filling process.
Marketing authorisations granted in December 2020
Parallel import licences granted in December 2020
Keep up to date with the latest information from the UK GLP monitoring authority.
Takeda UK Limited is recalling a batch of Instanyl 100mcg nasal spray solution (EU/1/09/531/015) due to the observation of cracked vials during inspection of the bulk vials and release testing of the finished products.
List of manufacturers and their medical devices which have been granted an exemption by the MHRA. The list also includes manufacturers whose exemption expired or was cancelled. This information will be listed for 2 months after expiry or cancellation.
List of field safety notices (FSNs) from medical device manufacturers from 11 January to 15 January 2021
Public list of companies in the UK who have had their licence/registration to manufacture or wholesale medicines/ingredients revoked or suspended.
How to notify the MHRA of your intention to carry out a clinical investigation for medical devices.
How to make a payment to MHRA by credit or debit card or a bank transfer.
Guidance on managing and using bed rails safely.
How the ‘Written Confirmation’ process operates for active substances manufactured in Great Britain (England, Wales and Scotland).
How to get a parallel import licence for your medicine in the UK, including pharmacovigilance requirements and submitting your application.
Comply with good pharmacovigilance practice and prepare for an inspection.
List of field safety notices (FSNs) from medical device manufacturers from 04 January to 08 January 2021
The Consortium brings together 16 leading organisations, spanning the NHS, regulators, and leading third sector and charitable organisations
Information about the risks of taking valproate medicines during pregnancy.
For a marketing authorisation holder only; how to report a defect with a veterinary medicine.
Guidance for Marketing Authorisation Holders and holders of other types of authorisations on their responsibilities for veterinary pharmacovigilance and how to report suspected Adverse Events.
UK-Canada Regulatory Cooperation: Guidance on Veterinary Drug Simultaneous Reviews published.
The process for the simultaneous review of veterinary drug submissions by Health Canada’s Veterinary Drugs Directorate and the UK's Veterinary Medicines Directorate.
Product defect recall alert for Carprieve 5% w/v Small Animal Solution for Injection (Vm 02000/4229) by Norbrook Laboratories Ltd.
The Veterinary Medicines Directorate is recruiting one Non-Executive Director to the VMD’s Management Board and Audit and Risk Assurance Committee.
Report of the ten products for which most Special Import Certificates (SIC) have been issued by VMD in the UK.
Guidance for prescribing vets on the use of the cascade.
Marketing Authorisation Holders (MAHs) have informed the VMD of supply problems with the following lactating cow intramammary antibiotics.
How to legally run a business that deals with the wholesale of animal medicines (veterinary medicinal products) and the WDA Register.
Reporting against VMD published standards up to 31 March 2021
Details of seizure notice served following a parcel addressed to premises in Banbridge, County Down stopped at a Belfast Depot.
Details of seizure notice served following a parcel addressed to premises in Castlederg, County Tyrone stopped at a Belfast Depot.
A reminder about what to do when sending information and payments to the VMD whilst we continue to work remotely.
Definitive fees charged for applications under Schedule 7 of the Veterinary Medicines Regulations 2013.
Guidance for the pharmaceutical industry on importing and exporting veterinary medicines from 1 January 2021.
Guidance for the pharmaceutical industry on location and other authorised personnel requirements post transition period for existing marketing authorisations and applications submitted after 1 January 2021.
During the transition period, the Canada-EU Comprehensive Economic and Trade Agreement (CETA) continued to apply.
Explanation of what Pharmacovigilance means and who is responsible.
Guidance for the pharmaceutical industry on applying for an authorisation to manufacture veterinary medicines.
Companies will develop saRNA therapies to treat neurological diseases
Cabenuva consists of ViiV Healthcare’s cabotegravir and Janssen’s rilpivirine
Company has completed genetic analysis for UK and South African variants
Cost-effectiveness estimates 'uncertain', according to NICE
Drug approved to reduce the risk of cardiovascular death/heart failure hospitalisation
Large number of respondents reported feeling tired or exhausted
Over 400,000 people in the UK live with RA
Antibodies in blood of vaccinated individuals neutralised in vivo version of variant
PIM status was awarded on the basis of Phase IIb results of nirsevimab
Lipodystrophy is characterised by an abnormal distribution of fat in the body
UK biotech company will collaborate with Lawrence Livermore National Laboratory
Approximately one in five breast cancer cases in the EU are HER2-positive
Darzalex, Rozlytrek and Tavlesse among newly accepted drugs
CAR-T therapy receives NICE backing within weeks of EMA authorisation
Industry's GVA has increased to $1.8bn according to new ABPI Scotland report
Unit 2 Fleet Business Park, Sandy Lane, Church Crookham, Fleet, Hampshire, GU52 8BF
Pharmaceutical and Veterinary Licensed Distributor. WDA (H) 43703 & WDA (V) 43703.
- +44 (0)1252 260 460.
- +44 (0)1276 469 290
Monday to Friday - 09:30 – 18:30
Saturday & Sunday - Closed, Online Ordering Available
